Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

401 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients-a systematic review and meta-analysis.
Fazekas T, Széles ÁD, Teutsch B, Csizmarik A, Vékony B, Váradi A, Kói T, Lang Z, Ács N, Kopa Z, Hegyi P, Hadaschik B, Grünwald V, Nyirády P, Szarvas T. Fazekas T, et al. Among authors: hadaschik b. Prostate Cancer Prostatic Dis. 2023 Dec;26(4):665-672. doi: 10.1038/s41391-022-00626-2. Epub 2022 Dec 12. Prostate Cancer Prostatic Dis. 2023. PMID: 36509931 Free PMC article. Review.
Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance.
Radtke JP, Kuru TH, Bonekamp D, Freitag MT, Wolf MB, Alt CD, Hatiboglu G, Boxler S, Pahernik S, Roth W, Roethke MC, Schlemmer HP, Hohenfellner M, Hadaschik BA. Radtke JP, et al. Among authors: hadaschik ba. Prostate Cancer Prostatic Dis. 2016 Sep;19(3):283-91. doi: 10.1038/pcan.2016.16. Epub 2016 May 17. Prostate Cancer Prostatic Dis. 2016. PMID: 27184812
Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.
Reis H, van der Vos KE, Niedworok C, Herold T, Módos O, Szendrői A, Hager T, Ingenwerth M, Vis DJ, Behrendt MA, de Jong J, van der Heijden MS, Peyronnet B, Mathieu R, Wiesweg M, Ablat J, Okon K, Tolkach Y, Keresztes D, Nagy N, Bremmer F, Gaisa NT, Chlosta P, Kriegsmann J, Kovalszky I, Timar J, Kristiansen G, Radzun HJ, Knüchel R, Schuler M, Black PC, Rübben H, Hadaschik BA, Schmid KW, van Rhijn BWG, Nyirády P, Szarvas T. Reis H, et al. Among authors: hadaschik ba. Int J Cancer. 2018 Oct 1;143(7):1764-1773. doi: 10.1002/ijc.31547. Epub 2018 May 10. Int J Cancer. 2018. PMID: 29672836 Free article.
Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer.
Szarvas T, Sevcenco S, Módos O, Keresztes D, Nyirády P, Csizmarik A, Ristl R, Puhr M, Hoffmann MJ, Niedworok C, Hadaschik B, Maj-Hes A, Shariat SF, Kramer G. Szarvas T, et al. Among authors: hadaschik b. BJU Int. 2018 Oct;122(4):695-704. doi: 10.1111/bju.14415. Epub 2018 Jun 20. BJU Int. 2018. PMID: 29802777
Nuclear Localization of Robo is Associated with Better Survival in Bladder Cancer.
Krafft U, Reis H, Ingenwerth M, Kovalszky I, Becker M, Niedworok C, Darr C, Nyirády P, Hadaschik B, Szarvas T. Krafft U, et al. Among authors: hadaschik b. Pathol Oncol Res. 2020 Jan;26(1):253-261. doi: 10.1007/s12253-018-0447-z. Epub 2018 Jul 17. Pathol Oncol Res. 2020. PMID: 30019121 Free article.
401 results